Autolus Therapeutics
Logotype for Autolus Therapeutics plc

Autolus Therapeutics (AUTL) investor relations material

Autolus Therapeutics Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Autolus Therapeutics plc
Jefferies Global Healthcare Conference summary17 Nov, 2026

Commercial performance and adoption

  • AUCATZYL (obe-cel) generated $74M in its first launch year; second-year revenue reached $113M in the first 9 months, including $41M in Q3. FY guidance rose from $120M-$135M to $140M-$150M; revenue is now expected at $150M or higher.

  • The U.S. launch has reached 90 centers and the U.K. 20; second-year revenue is expected to increase ~100% YoY, supported by physician experience and peer communication.

  • U.S. coverage exceeds 80% of patients; expansion will target geographic gaps, referring centers with patient flow, and facilities where CAR T-trained physicians establish practices.

  • ROCCA real-world data covering about two-thirds of first-year patients showed no high-grade cytokine release syndrome, 3% higher-grade transient neurological toxicity, and clinical activity above 90%.

  • Adoption is expected to build gradually as physicians gain confidence and use obe-cel across more eligible patients; conference presentations and peer exchange are key potential catalysts.

Manufacturing and margins

  • Q3 gross margin was 57%; year-to-date gross margin was 44%. Production is expected to double versus last year with fewer manufacturing operators and staff.

  • Gross margin is targeted at 65%-70% by 2028, with the ALL business expected to be cash-flow positive in 2028.

  • Margin improvement is expected from higher production volume spreading fixed costs and continued operational efficiency work across manufacturing steps.

Label and market expansion

  • The pediatric pivotal study is expected to complete enrollment by year-end or very early next year; data are expected at ASH next year, with an sBLA filing ready around that time.

  • Investigator-led frontline studies use two induction chemotherapy cycles followed by obe-cel consolidation, aiming to shorten treatment from 18-36 months to 4-6 months; first MD Anderson data are expected late next year.

  • Discussions are underway with cooperative groups and the NCI on a potential randomized, label-enabling frontline study.

  • The U.S. adult relapsed/refractory ALL peak-sales opportunity is estimated at $500M; expansion across ages and treatment lines could exceed $1B.

  • The U.K. launched in early 2026 after NICE assessment and routine commissioning; sales are expected to reach roughly 10% of U.S. sales. European launches may begin around 2028 if reimbursement and cost of goods support attractive economics; Europe potential was estimated at 20%-25%.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Autolus Therapeutics earnings date

Logotype for Autolus Therapeutics plc
Q4 202625 Mar, 2027
Autolus Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Autolus Therapeutics earnings date

Logotype for Autolus Therapeutics plc
Q4 202625 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Autolus Therapeutics plc is a clinical-stage biopharmaceutical company engaged in the development of advanced T-cell therapies for the treatment of cancer. The company leverages its proprietary technologies to engineer CAR T-cell therapies aimed at providing life-changing benefits to patients with various cancer types. Some of their key clinical-stage programs focus on therapies for conditions such as adult acute lymphoblastic leukemia and multiple myeloma. Autolus was founded in 2014, following innovative developments in cell programming technology at University College London. The company is headquartered in London, United Kingdom, and its shares are listed on the Nasdaq.